指南与共识心外重症与机械循环支持

心脏移植中抗体的管理:国际心肺移植学会(ISHLT)共识文件

The management of antibodies in heart transplantation: An ISHLT consensus document.
指南 / 共识 · J Heart Lung Transplant · 2018-01-31

该共识由来自75个中心的103名参与者参加的国际共识会议制定,讨论心脏移植术前和术后抗体的管理。会议通过专家报告、小组讨论和复会建立共识,涉及哪些抗体具有临床相关性、治疗哪些患者及何种治疗最有效安全等问题,并指出缺乏前瞻性试验数据。

要点

  • 抗体是心脏移植术前和术后患者发病和死亡的重要原因。
  • 预致敏患者数量增加,可能与大剂量机械循环支持装置使用增多有关。
  • 管理抗体的难点在于临床相关性不确定及缺乏前瞻性试验数据。

核心结论

  • 抗体仍是心脏移植术前和术后患者发病和死亡的重要原因,管理上存在不确定性且缺乏前瞻性试验数据。

研究设计与样本

  • 国际共识会议,由来自75个中心的103名参与者参加,通过专家报告、小组讨论和复会建立共识。

主要发现

  • 预致敏患者数量增加,趋势可能与大剂量机械循环支持装置使用增多有关。
  • 未预致敏的患者移植后也可产生供体特异性抗体,与更差结局相关。
  • 管理抗体的难点在于不确定哪些抗体具有临床相关性、治疗哪些患者及何种治疗最有效安全。

局限性

  • 原文指出缺乏前瞻性试验数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite the successes from refined peri-operative management techniques and immunosuppressive therapies, antibodies remain a serious cause of morbidity and mortality for patients both before and after heart transplantation. Patients awaiting transplant who possess antibodies against human leukocyte antigen are disadvantaged by having to wait longer to receive an organ from a suitably matched donor. The number of pre-sensitized patients has been increasing, a trend that is likely due to the increased use of mechanical circulatory support devices. Even patients who are not pre-sensitized can go on to produce donor-specific antibodies after transplant, which are associated with worse outcomes. The difficulty in managing antibodies is uncertainty over which antibodies are of clinical relevance, which patients to treat, and which treatments are most effective and safe. There is a distinct lack of data from prospective trials. An international consensus conference was organized and attended by 103 participants from 75 centers to debate contentious issues, determine the best practices, and formulate ideas for future research on antibodies. Prominent experts presented state-of-the-art talks on antibodies, which were followed by group discussions, and then, finally, a reconvened session to establish consensus where possible. Herein we address the discussion, consensus points, and research ideas.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Kobashigawa J, Colvin M, Potena L, et al. The management of antibodies in heart transplantation: An ISHLT consensus document. J Heart Lung Transplant. 2018. PMID: 29452978. doi:10.1016/j.healun.2018.01.1291

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。